ICIs and interleukin-2 (IL-2) by conjugation (for antibodies) or recombinant fusion (for cytokine) to the von Willebrand factor A3 domain (a collagen-binding domain) eradicated tumors and exhibited obvious safety and efficacy in a breast cancer model (Ishihara et al., 2019). This evidence concerns the gene IL2 and breast carcinoma.